Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Beheer van matig postoperatief recidief bij de ziekte van Crohn: een gerandomiseerd gecontroleerd onderzoek naar therapeutische escalatie, het POMEROL-onderzoek. (POMEROL) (POMEROL)

Study type : A 30 months, multicentre, open-label strategic randomized controlled trial

Population : Chron's Disease (CD) patients with an i2 endoscopic postoperative recurrence in the year following ileocolonic resection (6-12months after ileocolonic resection).

Treatments :

Stratification at inclusion according to prophylactic therapy.

Patients randomized in 2 arms:

  • Status quo arm: if the patient received no prophylactic therapy, no treatment will be started; if the patient received a prophylactic therapy, the same will be continued at the same dose.
  • Therapy escalation arm: infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.

Main objective : To evaluate the proportion of CD patients without endoscopic postoperative recurrence (i0-i1) at 12 months in the arm receiving therapy escalation compared to status quo arm in patients having an i2 endoscopic postoperative recurrence 6-12months after ileocolonic anastomosis with restoration of faecal stream.

Studie Overzicht

Gedetailleerde beschrijving

Number of patients : 360 patients in approximatively 25 sites in France.

Recruitement period : The trial duration for each patients will be 12 months from radomization (18 to 24 months from screening (ie : post-operatively))

Endpoints:

Primary endpoints: Proportion of patients with an i0-i1 modified Rutgeerts score at 12 months.

Secondary endpoints:

  • Proportion of patients with an i3-i4 modified Rutgeerts score at 12 months

  • Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months

  • Proportion of patients with an i0 modified Rutgeerts score at 12 months

  • PRO2 score at 12 months

  • Clinical postoperative recurrence within 12 months: average daily SF ≥ 3.5 and average daily AP score ≥ 1.5, AND

    • increased CRP compared to inclusion, at least + 10 mg/l
    • OR increased fecal calprotectin compared to inclusion, at least + 250 μg/g
  • Surgical recurrence within 12 months: need for a new ileocolonic resection

  • Endoscopic dilatation within 12 months: need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy

  • Time to clinical postoperative recurrence

  • Serious adverse events

  • Quality of life: EQ5D-5L questionnaire

  • Work productivity: Work Productivity and Activity Impairment questionnaire

Studietype

Ingrijpend

Inschrijving (Werkelijk)

213

Fase

  • Fase 4

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 75 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Crohn's disease diagnosed according usual criteria
  • Bowel resection with ileocolonic anastomosis performed removing all inflammatory lesions
  • Postoperative endoscopy performed between 6 and 12 months after ileocolonic anastomosis reaching the neoterminal ileum (patients who underwent a two stage surgical procedure are also eligible if the endoscopic evaluation is performed 6-12 months after restoration of the fecal stream)
  • Moderate endoscopic postoperative recurrence classified i2 according to the Rutgeerts score at 6-12 months, validated by a blinded central reading

Exclusion Criteria:

  • Patients with an ostomy
  • Ulcerative colitis or IBD type unclassified
  • Ileorectal or ileal pouch-anal anastomosis
  • Symptoms defined as average daily SF ≥ 3.5 and average daily AP score ≥ 1.5 having started after a free interval without symptoms of at least one month after surgery
  • Patients with obstructive symptoms of CD defined by a CDOS > 4
  • Patients exposed to infliximab before index surgery with a primary non-response (no clinical effect after 2 infusions at the discretion of the treating gastroenterologist) or history of infusion reactions to infliximab or history of detectable anti-infliximab antibodies
  • Patients treated with biological therapy (except for intraocular injections) or an investigational medical product after index surgery
  • Patients having started thiopurines or methotrexate more than 6 weeks after ileocolonic anastomosis with restoration of the fecal stream
  • Patients in whom not all inflammatory lesions have been removed at index surgery
  • Patients with active perianal Crohn's disease
  • Patients with a contraindication to infliximab: cancer in the 5 years prior to inclusion excluding non-melanoma skin cancer, active tuberculosis or untreated latent tuberculosis, moderate or severe heart failure, HIV or HBV infection (serology < 6 months), recent live vaccination (within 4 weeks of baseline)
  • Pregnant women
  • Patients under legal protection or unable to express their consent.
  • Patients not affiliated to a health insurance system.
  • Patients deprived of liberty by judiciary or administrative decision or hospitalized without consent or admitted in a sanitary or social institution for another reason than research.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Ander: Status quo arm

If the patient received no prophylactic therapy after resection, no treatments will be started.

If the patient received a prophylactic therapy after resection, the same will be continued at the same dose.

Stratification 1 : No treatments

Stratification 2 : Immunosuppressors at same dose

Experimenteel: Therapy escalation arm

Infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.

Stratification 1: Infliximab-CT-P13

Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors

Andere namen:
  • Remsima

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of patients with an i0-i1 modified Rutgeerts score at 12 months.
Tijdsspanne: Month12

Number of patients with an i0-i1 modified Rutgeerts score at 12 months.

Month12

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of patients with an i3-i4 modified Rutgeerts score at 12 months
Tijdsspanne: Month 12

Number of patients with an i3-i4 modified Rutgeerts score at 12 months

Month 12
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months
Tijdsspanne: Month 12

Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months

Month 12
Proportion of patients with an i0 modified Rutgeerts score at 12 months
Tijdsspanne: Month 12

Proportion of patients with an i0 modified Rutgeerts score at 12 months

Month 12
Patient Reporting Outcome score at 12 months.
Tijdsspanne: Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12

Patient Reporting Outcome score at 12 months will be assessed for the evaluation of disease activity (clinical remission).

Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12
Clinical postoperative recurrence
Tijdsspanne: Baseline, Month 4, Month 8, Month 12

Clinical postoperative recurrence within 12 months defined by : Average daily Stool Frequency ≥ 3.5 and average daily Abdominal Pain score ≥ 1.5, AND

  • increased CRP compared to inclusion, at least + 10 mg/l
  • OR increased fecal calprotectin compared to inclusion, at least + 250 μg/g

Average daily Stool frequency, average daily Abdominal Pain score, CRP and Calprotectin feacal will be combined to report the clinical postoperative recurrence (this outcome is is expressed without units)

Baseline, Month 4, Month 8, Month 12
Surgical recurrence within 12 months
Tijdsspanne: Baseline, Month 4, Month 8, Month 12

Surgical recurrence within 12 months defined by need for a new ileocolonic resection. Proportion of surgical recurrence within 12 months

Baseline, Month 4, Month 8, Month 12
Endoscopic dilatation within 12 months
Tijdsspanne: Baseline, Month 4, Month 8, Month 12

Endoscopic dilatation within 12 months defined by a need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy Proportion of endoscopic dilatation within 12 months

Baseline, Month 4, Month 8, Month 12
Time to clinical postoperative recurrence will be assessed
Tijdsspanne: Baseline, Month 4, Month 8, Month 12

Time to clinical postoperative recurrence will be assessed

Baseline, Month 4, Month 8, Month 12
Serious adverse events
Tijdsspanne: Screening, Baseline, Month 4, Month 8, Month 12

Occurence of Serious Adverse Events

Screening, Baseline, Month 4, Month 8, Month 12
Quality of life: EQ5D-5L questionnaires
Tijdsspanne: Baseline, week 2, week 6, Month 4, Month 8, Month 12

Quality of life will be assessed with the EQ5D-5L questionnaire

Baseline, week 2, week 6, Month 4, Month 8, Month 12
Work productivity and activity impairement questionnaires
Tijdsspanne: Baseline, week 2, week 6, Month 4, Month 8, Month 12

Work productivity and activity impairement will be assessed with work productivity and activity impairement questionnaires

Baseline, week 2, week 6, Month 4, Month 8, Month 12

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

21 december 2021

Primaire voltooiing (Werkelijk)

15 oktober 2026

Studie voltooiing (Werkelijk)

15 oktober 2026

Studieregistratiedata

Eerst ingediend

18 augustus 2021

Eerst ingediend dat voldeed aan de QC-criteria

28 september 2021

Eerst geplaatst (Werkelijk)

11 oktober 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren